Mayank Mamtani Analyst Performance

Senior Managing Director & Group Head of Healthcare at B. Riley Financial

Mayank Mamtani is a stock analyst at B. Riley Financial focused in the medical sector, covering 35 publicly traded companies. Over the past year, Mayank Mamtani has issued 32 stock ratings, including strong buy, buy, and hold recommendations. While full access to Mayank Mamtani's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mayank Mamtani's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 137 Last 7 Years
Buy Recommendations: 94.66% 124 Buy Ratings
Companies Covered: 35 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	3.8%	5 ratings
Buy	90.8%	119 ratings
Hold	5.3%	7 ratings
Sell	0.0%	0 ratings

Out of 131 total stock ratings issued by Mayank Mamtani at B. Riley Financial, the majority (90.8%) have been Buy recommendations, followed by 5.3% Hold and 3.8% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
TGTX
Nov 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
NVAX
Apr 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	88.6% of companies on NASDAQ	31 companies
OTCMKTS	5.7% of companies on OTCMKTS	2 companies
NYSEAMERICAN	2.9% of companies on NYSEAMERICAN	1 company
NYSE	2.9% of companies on NYSE	1 company

Mayank Mamtani, an analyst at B. Riley Financial, currently covers 35 companies listed on NASDAQ, OTCMKTS, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 34 companies	97.1%
	Manufacturing 1 company	2.9%

Mayank Mamtani of B. Riley Financial specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 21 companies	60.0%
MED - DRUGS 10 companies	28.6%
BIOTECHNOLOGY 2 companies	5.7%
MED PRODUCTS 1 company	2.9%
PHARMACEUTICAL PREPARATIONS 1 company	2.9%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
MGNX MacroGenics	4/10/2026	Upgrade	$3.44	$9.00	Buy
TBPH Theravance Biopharma	4/7/2026	Boost Price Target	$16.42	$17.00	Neutral
HROW Harrow	4/7/2026	Reiterated Rating	$34.91	$65.00	Buy
LCTX Lineage Cell Therapeutics	3/25/2026	Boost Price Target	$1.60	$4.00	Buy
CLYM Climb Bio	3/24/2026	Initiated Coverage	$6.54	$26.00	Buy
CLYM Climb Bio	3/23/2026	Upgrade	$6.98		Strong-Buy
ARCT Arcturus Therapeutics	3/18/2026	Initiated Coverage	$6.39	$22.00	Buy
ARCT Arcturus Therapeutics	3/17/2026	Upgrade	$6.72		Strong-Buy
TBPH Theravance Biopharma	3/4/2026	Reiterated Rating	$13.96	$14.00	Neutral
NKTR Nektar Therapeutics	2/23/2026	Reiterated Rating	$71.87	$150.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
CYTK Cytokinetics	1/21/2026	Boost Price Target	$63.78	$108.00	Buy
MDGL Madrigal Pharmaceuticals	12/11/2025	Boost Price Target	$552.47	$670.00	Buy
IRD Opus Genetics	12/10/2025	Initiated Coverage	$2.39	$9.00	Buy
CNTA Centessa Pharmaceuticals	12/1/2025	Boost Price Target	$29.11	$42.00	Buy
ZYME Zymeworks	11/21/2025	Reiterated Rating	$23.82	$40.00	Buy
NUVB Nuvation Bio	11/19/2025	Initiated Coverage	$4.80	$12.00	Buy
CYTK Cytokinetics	11/10/2025	Reiterated Rating	$61.01	$90.00	Buy
NVAX Novavax	11/10/2025	Reiterated Rating	$7.23	$16.00	Buy
TGTX TG Therapeutics	11/4/2025	Upgrade	$33.81		Strong-Buy
ZYME Zymeworks	10/10/2025	Initiated Coverage	$16.92	$30.00	Buy
HROW Harrow	10/1/2025	Reiterated Rating	$48.18	$74.00	Buy
MDGL Madrigal Pharmaceuticals	9/29/2025	Boost Price Target	$439.05	$560.00	Buy
NKTR Nektar Therapeutics	9/23/2025	Boost Price Target	$58.63	$105.00	Buy
HROW Harrow	9/23/2025	Boost Price Target	$48.61	$70.00	Buy
CYTK Cytokinetics	9/22/2025	Boost Price Target	$49.04	$80.00	Buy
TGTX TG Therapeutics	9/17/2025	Boost Price Target	$32.51	$55.00	Buy
TBPH Theravance Biopharma	9/12/2025	Initiated Coverage	$13.70	$28.00	Buy
TBPH Theravance Biopharma	9/11/2025	Upgrade	$14.30		Strong-Buy
ACTU Actuate Therapeutics	8/26/2025	Initiated Coverage	$7.98	$20.00	Buy
ALT Altimmune	8/13/2025	Lower Price Target	$3.62	$18.00	Buy
MNOV MediciNova	6/16/2025	Upgrade	$1.31	$5.00	Strong-Buy
MGNX MacroGenics	5/20/2025	Lower Price Target	$1.57	$3.00	Neutral
HROW Harrow	4/1/2025	Lower Price Target	$25.23	$65.00	Buy
VXRT Vaxart	3/27/2025	Lower Price Target	$0.45	$2.00	Buy
TRVI Trevi Therapeutics	3/19/2025	Reiterated Rating	$6.69	$20.00	Buy
LCTX Lineage Cell Therapeutics	3/14/2025	Lower Price Target	$0.52	$3.00	Buy
DNLI Denali Therapeutics	3/5/2025	Reiterated Rating	$16.06	$35.00	Buy
ARWR Arrowhead Pharmaceuticals	2/14/2025	Reiterated Rating	$19.75	$38.00	Buy

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.